Jasper Therapeutics, Inc. (JSPR)

NCM – Real vaqt narxi. Valyuta: USD

1.05

-0.06 (-5.41%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

1.05

+0.00 (0.47%)

Bozordan keyin: Mar 27, 2026, 6:17 PM EDT

Kompaniya haqida

Jasper Therapeutics, Inc., klinik tadqiqot bosqichidagi biotexnologiya kompaniyasi, mast va gematopoez hujayralari tomonidan boshqariladigan kasalliklarni davolash uchun terapiya ishlab chiqishga qaratilgan. Kompaniyaning asosiy mahsulot nomzodi briquilimab bo'lib, u mast va ildiz hujayralaridagi CD117 retseptoriga bog'lanish va signal berish uchun ildiz hujayrasi omilini bloklash uchun mo'ljallangan monoklonal antiteladir. U surunkali spontan ürtiker, surunkali indüklenebilir ürtiker va astma, shuningdek, o'roqsimon hujayrali anemiya, Fanconi anemiyasi va og'ir kombinatsiyalangan immunitet tanqisligi bo'lgan bemorlarda ildiz hujayralari transplantatsiyasi uchun konditsioner vositalar kabi turli mast hujayralari tomonidan boshqariladigan kasalliklarga chalingan bemorlar uchun terapevtik vositalarni ishlab chiqish va tijoratlashtirishga qaratilgan. Jasper Therapeutics, Inc. 2018-yilda tashkil etilgan va Redwood City, Kaliforniyada joylashgan.

Asosiy rahbarlar

Ism	Lavozim
Alex Gray	Head of Investor Relations
Dr. Daniel C. Adelman M.D.	Acting Chief Medical Officer, Member of Scientific Advisory Board & Senior Clinical Advisor
Dr. Judith Anne Shizuru M.D., Ph.D.	Co-Founder, Member of Scientific Advisory Board & Director
Dr. Luca Di Noto Ph.D.	Senior Vice President of Technical Operations
Mr. Herbert C. Cross CPA	CFO & Corporate Secretary
Mr. Jeetinder Singh Mahal M.B.A.	President, COO, CEO & Director
Mr. Matthew Ford	Senior Vice President of Human Resources